Tampere University Hospital, Dept of Haematology
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rimpilainen, Johanna
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
ALLTogether1, NCT04307576 / 2018-001795-38: A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Recruiting
3
6430
Europe, RoW
Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy, Besponsa+Maintenance Therapy, Imatinib, 6-tioguanine+Standard Maintenance Therapy, Blinatumomab, Blincyto
Mats Heyman, The Swedish Research Council, The Swedish Childhood Cancer Foundation, Pfizer, Servier, NordForsk, Aamu Pediatric Cancer Foundation, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Clinical Trial Center North (CTC North GmbH & Co. KG), Belgium Health Care Knowledge Centre, Karolinska Institutet, Cancer Research UK, Fundação Rui Osório de Castro, Acreditar - Associação de Pais e Amigos das Crianças com Cancro, Grupo Português De Leucemias Pediátricas, Amgen, Nova Laboratories Limited, Danish Child Cancer Foundation, Danish Cancer Society, The Novo Nordic Foundation, Assistance Publique - Hôpitaux de Paris, Direction Générale de l'Offre de Soins
Leukemia, Acute Lymphoblastic
06/27
06/32
NCT03911128: A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Recruiting
N/A
500
Europe, RoW
Observational
Mats Heyman, Nordic Society for Pediatric Hematology and Oncology, The Swedish Childhood Cancer Foundation, NordForsk
Leukemia, Acute Lymphoblastic
08/28
08/30
Rimpiläinen, Johanna
ALLTogether1, NCT04307576 / 2018-001795-38: A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Recruiting
3
6430
Europe, RoW
Omitted Doxorubicin, Omitted Vincristine+Dexamethasone pulses, Inotuzumab Ozogamicin+Standard Maintenance Therapy, Besponsa+Maintenance Therapy, Imatinib, 6-tioguanine+Standard Maintenance Therapy, Blinatumomab, Blincyto
Mats Heyman, The Swedish Research Council, The Swedish Childhood Cancer Foundation, Pfizer, Servier, NordForsk, Aamu Pediatric Cancer Foundation, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Clinical Trial Center North (CTC North GmbH & Co. KG), Belgium Health Care Knowledge Centre, Karolinska Institutet, Cancer Research UK, Fundação Rui Osório de Castro, Acreditar - Associação de Pais e Amigos das Crianças com Cancro, Grupo Português De Leucemias Pediátricas, Amgen, Nova Laboratories Limited, Danish Child Cancer Foundation, Danish Cancer Society, The Novo Nordic Foundation, Assistance Publique - Hôpitaux de Paris, Direction Générale de l'Offre de Soins
Leukemia, Acute Lymphoblastic
06/27
06/32
BEXMAB, NCT05428969 / 2021-002104-12: A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies

Recruiting
1/2
181
Europe, US
Bexmarilimab, FP-1305, Azacitidine, Venetoclax, Venclyxto®
Faron Pharmaceuticals Ltd, Faron Pharmaceuticals Ltd
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
04/25
12/25
NCT03911128: A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

Recruiting
N/A
500
Europe, RoW
Observational
Mats Heyman, Nordic Society for Pediatric Hematology and Oncology, The Swedish Childhood Cancer Foundation, NordForsk
Leukemia, Acute Lymphoblastic
08/28
08/30

Download Options